GSK plc Overview
Pro stress-test →GSK plc is a British multinational pharmaceutical and biotechnology company that discovers, develops, and delivers medicines and vaccines. In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company maintains a diversified portfolio spanning specialty medicines, vaccines, and consumer health products across major therapeutic areas.
Strategic Profile
Pro stress-test →GSK's R&D pipeline currently includes 64 vaccines and specialty medicines in its four core therapeutic areas of infectious diseases, HIV, oncology and immunology/respiratory. The company wields its might across several therapeutic classes, including respiratory, antiviral, and vaccines, and has been growing its presence in oncology and immunology. In September 2025, the company announced Emma Walmsley was stepping down as chief executive at the beginning of 2026, with Luke Miels appointed as her replacement.
Competitive Landscape
Pro stress-test →AstraZeneca, Novartis, Merck & Co., Pfizer, and Johnson & Johnson are among GSK's primary competitors. GSK competes as a top-10 pharma player with particular strength in vaccines and specialty medicines, though faces competitive pressures from larger peers and specialized biotech companies in oncology and immunology.
Industry Context
GSK plc operates in Pharmaceutical and Biotechnology.
Key facts
Founded: 2000 · Headquarters: London, UK · Employees: 69,400 · Revenue: $42B · Market cap: $118B